Europlasma S.A.

As of December 31, 2024, Europlasma S.A. has 52.64M shares outstanding.

These figures are as of December 31, 2024. The EV/Sales ratio of 0.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2024, Europlasma S.A. maintains a current ratio of 0.77, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -122.63, indicating conservative leverage, while an interest coverage ratio of -8.32 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -28.27, reflecting losses generated across the asset base. Inventory turnover of 1.54 indicates how many times Europlasma S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on January 26, 2026, Europlasma S.A.'s stock has declined approximately 99.55% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 13.90.

Over the twelve months ended December 31, 2024, Europlasma S.A. posted a gross margin of 53.32, reflecting its pricing power and cost economics. The operating margin of -61.51 and net profit margin of -36.02 provide insight into operational efficiency.

As of December 31, 2024, Europlasma S.A. has an Altman Z-Score of -1.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.